Biodesix, Inc., a fully integrated molecular diagnostic company dedicated to personalizing medicine, today announced that the Phase III clinical trial data for its VeriStrat® test will be a featured abstract in the 2013 Best of ASCO meetings. Topics for the meeting are determined by a panel of medical oncology experts who select abstracts that demonstrate practice-changing science, from the 2013 Annual Meeting of the American Society of Clinical Oncology®. The series visits Chicago, Los Angeles and Boston throughout the month of August.